Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Radiotherapy & Radiosurgery
Actinium 225 therapy
What Actinium 225 therapy is, how targeted alpha therapy destroys metastatic prostate cancer cells while sparing healthy tissue, what clinical evidence says about PSA response and remission, how it compares with Lutetium 177 and external radiation, approximate costs in Turkey against the UK, US and Germany, eligibility criteria, treatment cycle steps, recovery, side effects and hospital checks.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Radiotherapy & Radiosurgery
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Actinium 225 Therapy
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Actinium 225 therapy in Turkey: what it is and how targeted alpha therapy works
Actinium 225 therapy is an advanced targeted radionuclide treatment for patients with metastatic castration-resistant prostate cancer that has progressed despite hormone therapy and chemotherapy. In targeted alpha therapy, the alpha-emitting radioisotope Actinium-225 is bonded to a carrier peptide, most commonly prostate-specific membrane antigen (PSMA) targeting molecules like PSMA-617. Administered intravenously, this conjugate travels through the bloodstream and binds directly to PSMA proteins on prostate cancer cells. Specialised hospitals providing actinium 225 therapy Turkey protocols deliver this systemic treatment under strict nuclear medicine supervision.
Unlike external radiation that passes through healthy tissues, targeted alpha therapy works internally at the cellular level. Once attached to the cancer cell, Actinium-225 releases high-energy alpha particles over a microscopic distance, destroying tumour DNA while sparing nearby healthy cells. This guide explains how the therapy works, clinical evidence, costs across countries, recovery, and safety. For broader oncology options, explore our guide to oncology treatments in Turkey.
How does targeted alpha therapy destroy metastatic cancer cells?
The biological power of Actinium-225 comes from high linear energy transfer (LET). Beta-emitting isotopes like Lutetium-177 release electrons that travel two to three millimetres through tissue with low linear energy transfer. While effective against larger tumours, beta radiation causes single-strand DNA breaks, which aggressive cancer cells can sometimes repair.
Actinium-225 emits alpha particles with an ultra-short path length of 40 to 100 micrometres—merely two to four cell diameters. This concentrated energy causes severe, double-strand DNA fractures in the cancer cell nucleus. Because double-strand breaks are virtually impossible for cells to repair, targeted alpha therapy triggers tumour cell death even in cancers resistant to chemotherapy, novel hormones, or prior beta radiation.
Does actinium 225 therapy actually work for advanced prostate cancer?
Clinical studies show that actinium 225 therapy produces meaningful tumour responses in patients with heavily pretreated metastatic prostate cancer. Research indicates that between 60% and 70% of patients achieve a PSA decline of 50% or more, often with visible tumour shrinkage on follow-up molecular imaging. Many patients also experience substantial relief from bone pain and reduced painkiller use.
Does actinium 225 therapy work as a permanent cure? The factual answer is no. Targeted alpha therapy is a disease-controlling treatment for stage 4 prostate cancer, not an eradicative cure. While many patients gain months or years of disease control, tumours can eventually adapt or lose PSMA expression. Additionally, because salivary glands express PSMA, dry mouth is a recognized dose-limiting side effect. Responsible teams explain these realities clearly and never promise guaranteed remission.
Actinium 225 therapy cost in Turkey compared with the UK, US and Germany
The cost of radioligand therapy reflects the complex production of Actinium-225, which requires specialized particle accelerators or generators. Because medical-grade Actinium-225 is produced in limited global quantities, the isotope represents a large part of the total price. The table below outlines approximate cost ranges per cycle and for a typical multi-cycle course; individual hospitals provide exact quotes after reviewing medical records.
| Country | Approximate cost per cycle | Typical course (2–4 cycles) |
|---|---|---|
| Turkey | €9,000 – €16,000 | €18,000 – €45,000 |
| United Kingdom | €22,000 – €38,000 | €45,000 – €90,000 |
| United States | €35,000 – €65,000 | €70,000 – €150,000 |
| Germany | €16,000 – €28,000 | €32,000 – €75,000 |
Variables affecting actinium 225 therapy cost include the administered dosage, the number of cycles, and whether tandem therapy with Lutetium-177 is planned. In Turkey, treatment packages generally cover baseline Ga-68 PSMA PET/CT scans, renal clearance tests (MAG3), the infusion, hospital observation, and airport transfers. When comparing an actinium 225 therapy price estimate, confirm in writing whether pre-therapy imaging and interim lab panels are included.
Actinium 225 therapy compared with Lutetium 177 and external radiation
Patients often compare Actinium-225 with alternative radiation treatments. Lutetium-177 PSMA is the standard beta-emitting radioligand. While Lutetium-177 has lower salivary toxicity, its longer radiation path can affect bone marrow when treating extensive bone metastases. In contrast, external techniques like tomotherapy or cranial procedures like gamma knife deliver focused external beams; they treat localized lesions effectively but cannot address widespread micro-metastases scattered across the skeleton.
| Treatment approach | Radiation type & target | Best suited to | Typical limits |
|---|---|---|---|
| Actinium-225 PSMA | Targeted alpha emitter; high energy over 2–4 cell diameters | Extensive micrometastases, bone marrow infiltration, post-Lutetium progression | Salivary gland toxicity (dry mouth); restricted isotope supply |
| Lutetium-177 PSMA | Targeted beta emitter; moderate energy over 1–2 mm path length | First-line radioligand therapy for PSMA-positive metastatic prostate cancer | Cross-fire radiation may affect bone marrow; acquired resistance |
| External radiotherapy | High-energy photons targeted externally to defined tumour sites | Focal primary tumours or isolated, painful bone lesions | Cannot treat widespread, diffuse micro-metastases throughout the body |
In selected cases, physicians recommend tandem therapy, combining lower doses of Actinium-225 with Lutetium-177 to balance tumour killing power while limiting radiation dose to salivary glands.
Who is an eligible candidate for actinium 225 PSMA therapy?
Determining eligibility for actinium 225 PSMA therapy requires thorough screening to verify target receptor expression and organ reserve. Patients undergo a gallium-68 (68Ga) or fluorine-18 (18F) PSMA PET/CT scan to confirm strong tracer uptake across all metastatic lesions.
Key eligibility criteria include:
- Progressive metastatic castration-resistant prostate cancer despite standard hormonal therapies or chemotherapy.
- Adequate bone marrow reserve: haemoglobin > 9 g/dL, platelets > 100,000/µL, and adequate white blood cells.
- Sufficient kidney function confirmed by blood tests and MAG3 renal clearance scintigraphy.
- An ECOG performance score of 0 to 2, indicating daily physical independence.
Patients are not eligible if scans reveal PSMA-negative lesions, severe kidney failure, profound bone marrow exhaustion, or acute spinal cord compression requiring immediate surgical intervention.
What happens during an Actinium-225 treatment cycle?
Each treatment cycle follows a protocol directed by nuclear medicine specialists and radiation safety officers. Pre-treatment blood work, kidney clearance assessment, and imaging are completed first. On infusion day, intravenous hydration begins to support renal clearance.
To protect the salivary glands, ice packs are placed over the parotid and submandibular areas thirty minutes prior to administration. Cooling constricts local capillaries and reduces isotope uptake. Actinium-225 is infused intravenously over ten to fifteen minutes through an indwelling cannula. The procedure causes minimal discomfort, feeling like a routine saline drip.
After the infusion, patients rest in a monitored nuclear medicine ward. Because alpha radiation travels only a fraction of a millimetre, external exposure to others is negligible. However, body fluids carry trace radioactivity for 24 to 48 hours, so patients drink extra fluids and follow simple hygiene guidelines before receiving discharge clearance.
Realistic results: what can patients expect from before and after scans?
Response is evaluated through regular PSA blood tests and follow-up PET/CT imaging. Patients should maintain clear expectations regarding what before-and-after evaluations show. A favourable response typically brings a steady fall in PSA levels within four to eight weeks, alongside visibly decreased tracer uptake on scans.
Before-and-after imaging often demonstrates the fading or clearance of active lesions in bones and lymph nodes. Many patients experience notable pain relief and reduced need for painkillers. However, imaging cannot confirm the elimination of microscopic cancer cells, and a clear scan does not equate to a permanent cure. Ongoing clinical follow-up is necessary to monitor long-term disease stability.
Your trip to Turkey, treatment intervals and recovery
Patients travelling for actinium 225 therapy in Turkey usually stay five to seven nights per cycle. This schedule covers pre-treatment blood tests and PET/CT imaging on Days 1 and 2, isotope infusion on Day 3, observation on Day 4, and a final safety review before flying home on Day 5 or 6.
Day-to-day actinium 225 therapy recovery is generally manageable compared with chemotherapy. Patients do not experience hair loss or severe gastrointestinal distress. Mild tiredness and subtle taste changes are common in the first week and ease with rest and fluids. For two to three days post-infusion, patients observe basic precautions, such as maintaining a one-metre distance from others and avoiding prolonged contact with young children or pregnant women. Cycles are repeated every six to eight weeks, typically for two to four cycles.
Potential side effects and safety considerations
While targeted alpha therapy offers cellular precision, it carries known side effects documented by nuclear medicine societies:
- Xerostomia (dry mouth): Because salivary glands express PSMA receptors, they absorb small amounts of radiation. This can cause persistent mouth dryness and altered taste. Salivary cooling during infusion and hydration help reduce its severity.
- Bone marrow suppression: Temporary declines in red blood cells, platelets, or white blood cells can occur, particularly in men with extensive skeletal metastases. Blood counts are monitored between cycles.
- Renal function: Radioactive conjugates are filtered by the kidneys. While alpha particles cause minimal cross-fire to renal tissue, pre-existing kidney impairment requires cautious dosing.
- Transient fatigue and nausea: Mild lethargy or fleeting nausea may appear within 48 hours and responds well to standard antiemetic medication.
How to evaluate a nuclear medicine hospital and red flags
Because Actinium-225 requires specialized radiopharmacy synthesis and radiation containment, choosing an accredited hospital is crucial.
Important questions to ask the clinic include:
- Are the nuclear medicine physicians board-certified specialists experienced in targeted alpha therapies?
- Is the Actinium-225 obtained from licensed, GMP-certified suppliers with verified radiochemical purity?
- Do you perform on-site PSMA PET/CT scans to confirm target receptor expression before therapy?
- Does a multidisciplinary tumour board review my case before treatment is approved?
- What protocols are used during infusion to protect salivary glands and kidneys?
- How will my home doctor receive detailed treatment records and monitoring advice?
Red flags include clinics that offer Actinium-225 without reviewing recent PSMA PET/CT scans, promise guaranteed cure, quote prices without specifying isotope activity, or demand upfront deposits without a doctor consultation. To learn more about our process, read how it works and contact our medical team for a clinical evaluation and free quote.
Hospitals with Oncology in Turkey
Frequently asked questions
Actinium 225 therapy is an advanced targeted alpha therapy primarily used for metastatic castration-resistant prostate cancer. It pairs the alpha-emitting radioisotope Actinium-225 with a targeting carrier molecule, usually PSMA-617 or PSMA-I&T. The compound seeks out PSMA receptors on cancer cells, delivering destructive alpha radiation directly into the tumour while sparing surrounding healthy tissues.
Clinical research shows that Actinium-225 therapy can induce significant tumour regression and prostate-specific antigen (PSA) reductions, even in patients whose cancer progressed after chemotherapy and Lutetium-177 therapy. Studies report PSA drops of 50 percent or more in roughly 60 percent of heavily pre-treated individuals. However, it is an advanced disease-controlling treatment rather than a permanent cure.
The primary difference lies in the radiation type. Lutetium-177 emits beta particles, which travel up to two millimetres through tissue with lower linear energy transfer. Actinium-225 emits powerful alpha particles with a path length under 100 micrometres, causing complex double-strand DNA breaks. This makes Actinium-225 especially effective against micrometastases and tumours that have become resistant to beta radiation.
In Turkey, actinium 225 therapy typically costs between €9,000 and €16,000 per treatment cycle, compared with €22,000 to €38,000 in the UK or over €35,000 in the US. A full course usually involves two to four cycles. The final price depends on the isotope dosage, pre-treatment PET/CT imaging, kidney function scintigraphy and hospital accommodation.
The most common side effect is dry mouth (xerostomia), because salivary glands express PSMA receptors and absorb small amounts of the radiopharmaceutical. Other potential effects include transient fatigue, mild nausea, and temporary decreases in blood cell counts (anaemia or thrombocytopenia). Cooling salivary glands with ice packs during administration helps mitigate the severity of mouth dryness.
Eligible patients typically have metastatic castration-resistant prostate cancer that has progressed despite hormone therapy or chemotherapy. Candidates must undergo a gallium-68 or fluorine-18 PSMA PET/CT scan confirming high PSMA expression across tumour sites. They also require adequate kidney, liver, and bone marrow reserves to safely process the radiopharmaceutical and clear decay products.
The intravenous infusion causes minimal discomfort, feeling similar to a routine saline drip. Patients do not feel the radiation working inside the body. In the days following administration, some individuals experience mild tiredness, nausea, or altered taste, which are managed with routine supportive medications and hydration.
Duration of disease control varies depending on tumour volume, prior therapies, and individual cancer biology. Clinical evidence indicates that many patients experience disease stabilization, pain relief, and lowered PSA levels lasting between six and eighteen months. Follow-up scans and regular blood tests monitor the ongoing response to determine whether further cycles are required.
Patients travelling to Turkey generally need to stay for five to seven days per cycle. This window allows adequate time for preliminary blood work, baseline PSMA PET/CT imaging, pre-infusion hydration, isotope administration, post-therapy safety monitoring, and a clearance consultation before flying home. Subsequent cycles take place six to eight weeks later.
Before-and-after PSMA PET/CT scans compare the metabolic activity and extent of metastatic lesions across the bones, lymph nodes, and soft tissues. A positive response shows a noticeable decrease or complete disappearance of tracer uptake in tumours, often accompanied by falling serum PSA levels. Scans also confirm that healthy organs remain unaffected.
Patient stories